Floatz logo

Alloreactive Ctl

Malignant Meningioma

Jonsson Comprehensive Cancer CenterCell therapyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Malignant Meningioma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Essen Biotech
Phase 2B
Fludarabine
Essen Biotech
Phase 2B
Rvp-001
Reveal Pharmaceuticals Inc.
Phase 2B
Nivolumab
National Cancer Institute (NCI)
Phase 2B
Anti-Ny Eso-1 Mtcr Pbl
National Cancer Institute (NCI)
Phase 2B

View all 19 →

Same molecule, other indications

Alloreactive Ctl is also rated in:

gliomaDormant
CC
Indicative ·
47 / 100
View asset →
anaplastic oligodendrogliomaDormant
CC
Indicative ·
47 / 100
View asset →
anaplastic oligoastrocytomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →